{
  "intro": {
    "heading": "Comprehensive biomarker testing at diagnosis can detect both <b>actionable</b> (eg, <i>EGFR, ALK</i>) and <b>emerging biomarkers</b> (eg, <i>KRAS G12C</i>)<sup class='sup osup'>3</sup>",
    "text3": "Consider testing eligible patients with NSCLC at diagnosis for <i>KRAS</i><sup class='sup osup'>10,11</sup>",
    "text8": "<i>ALK,</i> anaplastic lymphoma kinase; <i>EGFR,</i> epidermal growth factor receptor; <i>KRAS,</i> Kirsten rat sarcoma; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer; PCR, polymerase chain reaction.",
    "text10": "One Amgen Center Drive, <br class='mobile-show' style='display:none;'>Thousand Oaks, CA 91320-1799",
    "text11": "Â© 2020 Amgen Inc. All rights reserved. <br class='mobile-show' style='display:none;'><span class='lineblue'>USA-510-80168 11/20</span>",
    "text12": "If you prefer not to receive further messages from this center, please <a href='https://preferences.amgen.com/emailTriageMod.jsp?trg=etrgemod' target='_blank' style='color: #f47a20;'>click here</a> and confirm your request."
  }
  }
